Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the fo...
Radio and PodcastLive Radio & Podcasts
Science & Medicine
BioCentury This Week
A trusted and essential partner to the biopharmaceutical industry, providing 27 years of in-depth research, analysis and data on innovation and excellence —from biology to the patient.
BioCentury This Week Podcast Guide
Listen to BioCentury This Week, a Science & Medicine podcast by BioCentury. Stream 373 episodes in English, follow new audio stories, and play episodes online on Radio and Podcast.
Show Topic
Browse this show under Science & Medicine podcasts.
Episodes
20 episodes are loaded now from a catalog of 373. More episodes can be opened from this page.
Discover More
Explore Science & Medicine podcasts, South Korea podcasts and English podcasts.
Episodes
20 of 373 episodes
Ep. 362 - AACR: Data and de-risking
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Researc...
Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDA...
Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar polici...
Ep. 359 - 2Q markets preview, tariffs and biotech takeouts
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing...
Ep. 358 - Europe's biotech challenge
Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed t...
Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision
A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podc...
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCe...
Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline
Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to...
Ep. 354 - East-West Summit Takeaways
Biotechs in South Korea and other regions of Asia outside of China need to lean into innovation to distinguish themselves from their Chinese...
Ep. 353 - Prasad Departure and Future of Fibrosis Therapies
The second ousting of Vinay Prasad from FDA in the past eight months won’t lead to major changes at the agency, other than selecting a succe...
Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight
Can a strong U.S. biopharma industry be reconciled with the successful emergence of China? And can China be a catalyst of positive change ac...
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for mul...
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA
As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced proving...
Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch
2025 marked the end of a four-year slide in series A financings for biotechs, with 144 biotechs raising an aggregate of $8 billion, up $1 bi...
Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules
RNAi and exon-skipping therapies headline the list of regulatory and pivotal data catalysts in 2026, while new lipid-lowering mechanisms, mo...
Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos
New rules in China will accelerate the country’s cell and gene therapy sector by reshaping how investigator-initiated trials are conducted a...
Ep. 346 - 2026 Public Markets Preview
The biotech bull is back, and buysiders believe this market has staying power for the first time in nearly five years. On a special episode...
Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN
Next-generation induced proximity technologies are coming of age after a decade of industry focus on PROTACs. On the latest BioCentury This...
Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation
The J.P. Morgan Healthcare Conference kicked off this week with sunny skies over San Francisco and more financial momentum than the biotech...
Questions About BioCentury This Week
Where can I listen to BioCentury This Week episodes?
You can listen to BioCentury This Week episodes online on Radio and Podcast. Open an episode and the site player will stream the available audio.
What is BioCentury This Week about?
BioCentury This Week is listed as a Science & Medicine show. The show language is listed as English.
How many BioCentury This Week episodes are listed?
This page lists 373 episodes for BioCentury This Week. More episodes are available from the View more button when the list continues.
Quick Answers About BioCentury This Week
Where can I listen to BioCentury This Week?
You can listen to BioCentury This Week episodes on this page by opening an episode and using the site player.
What type of podcast is BioCentury This Week?
BioCentury This Week is listed as a Science & Medicine show by BioCentury.
How many episodes are available?
This page lists 373 episodes for BioCentury This Week where feed data is available.